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The leaves ofMorus alba L. have a long history in Traditional ChineseMedicine and also became valued by the ethnopharmacology
of many other cultures.The worldwide known antidiabetic use of the drug has been suggested to arise from a complex combination
effect of various constituents. Moreover, the drug is also a potential antihyperuricemic agent. Considering that type 2 diabetes
and hyperuricemia are vice-versa in each other’s important risk factors, the use of mulberry originated phytotherapeutics might
provide an excellent option for the prevention and/or treatment of both conditions. Here we report a series of relevant in vitro
and in vivo studies on the bioactivity of an extract of mulberry leaves and its fractions obtained by a stepwise gradient on silica
gel. In vivo antihyperglycemic and antihyperuricemic activity, plasma antioxidant status, as well as in vitro glucose consumption
by adipocytes in the presence or absence of insulin, xanthine oxidase inhibition, free radical scavenging activity, and inhibition
of lipid peroxidation were tested. Known bioactive constituents of M. alba (chlorogenic acid, rutin, isoquercitrin, and loliolide)
were identified and quantified from the HPLC-DAD fingerprint chromatograms. Iminosugar contents were investigated by
MS/MS, 1-deoxynojirimycinwas quantified, and amounts of 2-O-alpha-D-galactopyranosyl-1-deoxynojirimicin and fagominewere
additionally estimated.
1. Introduction
Chronically elevated uric acid concentration in the serumhas
impact on human health at various levels; it frequently leads
to the development of gout [1], and it is a relevant risk factor
of several further chronic diseases. For example, it represents
a significant risk for various cardiovascular and cerebrovas-
cular diseases [2–4], and a tight connection between hyper-
uricemia and diabetes has recently been revealed; apparently,
these two diseases mutually increase each other’s incidence
[5]. Hyperinsulinemia in type 2 diabetes can significantly
increase reabsorption of uric acid in the proximal tubules,
while its overproduction due to an increased activity of
xanthine-oxidase usually also takes place [5, 6]. On the other
hand, high uric acid levels might predict the development
of metabolic syndrome consequentially leading to diabetes
[7, 8] and can also increase severity of the already developed
disease by leading to a higher incidence of certain diabetic
complications [9]. The mechanism by which these metabolic
states are interconnected seems yet to be clarified, although
there is evidence that hyperuricemia, metabolic syndrome,
and type II diabetes share the same causal origin in which
insulin resistance would play a key role [5]. Anyhow, devel-
opment of novel therapeutic agents targeting both diabetes
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and hyperuricemia appears to be a highly relevant strategy for
overcoming difficulties attributed to the current therapeutic
approaches. Appropriately chosen phytotherapeutics [10, 11],
representing complex bioactivity profiles, might serve as
excellent tools to fulfill this objective, either as monotherapy
or in combination with already existing approaches.
Mulberry leaves are probably best known by their role
in the silk production, but medicinal use of this drug also
dates back at least two thousand years; it is alreadymentioned
in the “Divine Farmer’s Materia Medica” (pinyin: Shénnóng
Běncǎo J̄ıng) written during the reign of the Han dynasty.
In Traditional Chinese Medicine, leaves of M. alba possess
sweet, slightly bitter, and slightly cold properties, and their
primary uses are described as “to expel wind and heat
from the lungs, as well as to clear the liver and the eyes”
[12]. Anti-diabetic use of mulberry leaves had also been
popular; moreover, this indication became part of the local
traditional medicine wherever the tree has been naturalized
[13–16]. Based on this, a large number of herbal preparations
(including many food supplements) are worldwide available
for diabetes treatment and easily accessible to everyone even
via online shopping. This activity of mulberry leaves has
been verified by a number of studies including several animal
experiments [14–16] and a few human trials as well [17, 18],
but, to our knowledge, the active constituents and their role in
the activity still remain to be fully described. Nevertheless, a
complex cocktail of various bioactive constituents is thought
to be responsible for this activity [19], among which the role
of iminosugars [18] and certain phenolics mainly chlorogenic
acid and rutin [16] might be the most significant.
Furthermore, several traditional Chinese preparations
utilize the branch of Morus alba for the treatment of gout,
arthritis, and rheumatism [20]. Various constituents of the
drugwere found to have significant antihyperuricemic poten-
tial, including mulberroside A, a stilbene glycoside [21], and
a number of flavonoids, primarily morin [22, 23].
Based on the above, our objectives were to explore the
potential of Morus alba leaves as dual-target phytotherapeu-
tics to prevent and treat both diabetes and hyperuricemia
and to investigate whether a simple chromatographic frac-
tionation can lead to the enrichment of the main bioactive
constituents valuable for both therapeutic targets of interest.
2. Materials and Methods
2.1. Plant Material, Chemicals, and Reagents. The leaves of
Morus alba were collected near Ásotthalom (nearby Szeged,
Hungary) in May, 2007, and botanically identified by A.
Hunyadi. A voucher specimen (MA052007) was deposited in
the Institute of Pharmacognosy, University of Szeged, Szeged,
Hungary. All chemicals, if otherwise not specified, were
purchased from Sigma-Aldrich (Budapest, Hungary). Rutin
(2) and isoquercitrin (3) were purchased from ChromaDex
(Irvine, CA, USA) and Extrasynthése (Genay, France),
respectively. Loliolide (4) was previously isolated from the
dry leaves ofMorus alba [19], and 1-Deoxynojirimicin (1-DN)
was purchased fromWako Pure Chemical Industries (Osaka,
Japan). HPLC grade methanol was obtained from Fischer
Scientific; ultrapure water was obtained by using a Millipore
Direct-Q UV3 equipment.
2.2. Extraction and Chromatographic Fractionation. 2.5 kg
of the dried and ground plant material was extracted by
percolation with 30 L of 70% aqueous methanol and the
solvent was evaporated under vacuum at 50∘C to obtain
675.36 g dry extract (EX). 170 g of the drymaterial was further
processed; it was dissolved in 1000mL of water and extracted
with 10 × 500mL of n-butanol. After solvent evaporation,
dry residue of the aqueous (FR-W) and organic phase (FR-
B) was 78.4 and 88.09 g, respectively. The butanol phase was
adsorbed onto triple amount (276 g) of silica (Kieselgel 60,
Merck, Darmstadt, Germany) and administered on the top









: EtOH (95 : 5, 9 : 1, 8 : 2, 7 : 3,
6 : 4, and 1 : 1), and EtOH was used, and one single fraction
per solvent was collected. After the first fraction of 18 L, each
following was of 10 L volume. After solvent evaporation, dry
residues of the fractions were 13.72, 9.76, 4.48, 8.19, 10.52, 9.93,
5.50, and 10.87 g, respectively. Based on high similarities in
their TLC fingerprints, the last three fractions were joined;
hence, finally six fractions, referred to as FR1-6, were used for
the experiments discussed here.
2.3. HPLC-DAD Analysis of Fractions FR1-6. Diode-array
detected high performance liquid chromatography (HPLC-
DAD) was performed on a gradient system of two Jasco
PU2080 pumps connected to a Jasco MD-2010 Plus diode-
array detector (DAD) and equipped with a Jasco AS-
2055Plus autosampler (Jasco Co., Tokyo, Japan), by using
a Zorbax Eclipse XDB-C8 (5 𝜇m, 4.6 × 150mm) analytical
column. Samples were dissolved in 30% of aqueous MeOH at
2mg/mL, and 30 𝜇L of each was injected. Gradient elution
was performed from 30 to 100% of aqueous MeOH in 13
minutes, kept at 100% for four more minutes, and returned to
30% at 17.1min. Chromatograms were recorded for 24min,
and DAD data was collected from 200 to 650 nm. Baselines
were corrected by subtracting the chromatogram of a single
30 𝜇L injection of 30% MeOH.
2.4. Quantitative Analysis of Compounds 1–4. Single-point
quantitative analysis was performed for the previously iden-
tified major constituents in their respective fractions such
as chlorogenic acid (1), rutin (2), and isoquercitrin (3) in
EX, FR-B and FR5-6 and loliolide (4) in FR2. Calibration
curves were taken by analysing dilutions of a 1mg/mL stock
solution of the corresponding standard, at concentrations of 1,
0.5, 0.4, 0.3, 0.2, 0.1, and 0.05mg/mL. 𝑅2 values were 0.9970,
0.9990, 0.9904, and 0.9978 for the calibration lines of 1–4,
respectively. In case of FR5 and FR6, peaks of 2 and 3 were
partially overlapping; deconvolution was performed by using
Gaussian approximations with the Fityk 0.9.7 software (Free
Software Foundation, Poland) and quantities were calculated
based on the peak areas revealed this way.
2.5. Determination of Iminosugars. Iminosugar content was
qualitatively investigated by thin-layer chromatography
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(TLC) in each fraction, by using DC-Alufolien Kieselgel
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(3 : 6 : 2, v/v/v) as solvent system. For quan-
titative analysis, an API 2000 MS/MS spectrometer was used
with a Shimadzu autosampler and an electrospray ionization
(ESI) interface set in positive mode. 1-DN, 2-O-alpha-D-
galactopyranosyl-1-deoxynojirimicin (Gal-DN), and fagom-
ine contents were investigated in FR-W, FR-B, and FR4-6.
Injected sampleswerewashed into the spectrometerwith 50%
aqueous MeOH at a flow rate of 200 𝜇L/min; temperature
of the ion source was 300∘C. Multiple reaction monitoring
(MRM) was used with transitions of m/z 164→ 69 for 1-DN,
m/z 326→ 164 for GAL-DN, andm/z 148→ 86 for fagomine,
according to literature data [24]. Parameter optimization
and data acquisition and evaluation were performed by
using the Analyst 1.5.1 software. Calibration line of 1-DN
(𝑅2 = 1.0000) was obtained by means of six measurement
points in triplicates.
2.6. In Vitro Assay on Xanthine Oxidase (EC 1.17.3.2)
Inhibition. The activity of the enzyme was calculated from
the increase of uric acid concentration determined by
microplate-based kinetic photometry [25]. Briefly, the
absorption of uric acid generated from xanthine (50𝜇M at
start-up) was followed at 𝜆 = 290 nm for 125 s (Spectrostar
Nano, BMG Labtech, Ortenberg, Germany). The activity
of xanthine oxidase was described as the slope of the
absorbance versus time curve and allopurinol was used as
positive control. Stock solutions prepared with dimethyl-
sulfoxide were used for the in vitro assays and any substantial
effect of the solvent was excluded. All in vitro assays were
carried out in duplicates.
2.7. Determination of Free Radical Scavenging Activity by
DPPH Assay In Vitro. The activity for scavenging 1,1-
diphenyl-2-picrylhydrazyl (DPPH) radicals was tested for
each fraction as described earlier [26]. Briefly, different
amounts of the samples were added to 0.1mM DPPH dis-
solved in ethanol. The mixture was shaken and allowed to
stand for 30min, and then the absorbance of the solution
was measured at 𝜆 = 517 nm. trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid), a water-soluble ana-
log of vitamin E, was used as positive control.
2.8. Determination of Lipid Peroxidation Inhibitory Activity.
The antioxidant properties of the fractions were additionally
measured by means of inhibition of the autooxidation of
unsaturated fatty acids present in animal brain tissue [27].
A lipid-rich fraction was prepared from the brains of male
Sprague-Dawley rats (Charles River Laboratories, Budapest,
Hungary; body mass: 250–300 g) by homogenization and
centrifugation. The fatty acids in such a fraction get spon-
taneously oxidized during an incubation of 1 h at 37∘C, and
this oxidation can be inhibited by antioxidants. The oxidized
products were determined by colorimetry at 532 nm after
reaction with thiobarbituric acid. All in vitro experiments
were carried out in duplicates and statistically evaluated.
Sigmoid curves were fitted to the results of both antioxidant
assays, and IC
50
values were calculated by using GraphPad
Prism 4 (GraphPad Software, San Diego, CA, USA).
2.9. Testing the Effect on the Glucose Consumption of Adipo-
cytes. Effect of each fractionwas tested on the in vitro glucose
consumption of adipocytes as published before, at concentra-
tions of 200𝜇g/mL [19]. Briefly, 3T3-L1 preadipocytes (5×105
cells, BCRC no. 60159; Bioresource Collection and Research
Center, Taiwan) were seeded and cultured in 10% CS DMEM
containing 5.5mM D-glucose. The cells were induced to
differentiate, and, at day 3, samples dissolved in DMSO were
added to the cells at 200𝜇g/mL either in presence or absence
of 0.32 𝜇M insulin. 24 h changes in the glucose contents of the
testing media were recorded and compared to those before
the addition of the samples.
2.10. Animal Studies. Animals were treated in accordance
with the European Communities Council Directives
(86/609/ECC) and the Hungarian Act for the Protection
of Animals in Research (XXVIII.tv.32.§). Experiments
involving animal subjects were carried out with the approval
of the Hungarian Ethical Committee for Animal Research
(registration no. IV./01758-2/2008). Male Sprague-Dawley
rats (Charles River Laboratories, Budapest, Hungary; body
mass: 180–200 g; 8 animals in each group) were housed in
temperature (20–23∘C), humidity (40–60%), and light (12 h
of light, 12 h of dark) regulated rooms, with tap water and
rodent food (Bioplan, Isaszeg, Hungary) intake available
ad libitum. The tested extracts were orally administered in
0.25% methylcellulose containing 2% Cremophor EL using
a dosing volume of 5mL/kg. Three doses of all extracts (30,
60, and 120mg/kg) were selected for daily treatment for 3
consecutive days and each treatment was performed after
16 hours of fasting. One-way analysis of variance (ANOVA)
with Dunnett’s multiple comparison test by GraphPad Prism
4 was used for statistical evaluation of all in vivo experiments.
2.11. Determination of Antihyperuricemic, Antihyperglycemic,
and Antioxidant Properties of the Fractions In Vivo. In order
to minimize the number of animals, antihyperuricemic,
antihyperglycemic, and antioxidant properties effects were
determined from the same groups of rats. Experimental
hyperuricemiamodel induced by uricase inhibitor potassium
oxonate was utilized to assess the antihyperuricemic proper-
ties of the tested fractions [28]. 250mg/kg potassium oxonate
was suspended in 0.25% methylcellulose and administered
intraperitoneally at the time of the third oral treatment.
50mg/kg of allopurinol, a clinically used antigout drug, was
orally administered as a positive control. One hour later
rats were orally treated with 2.5 g/kg starch suspension in
a dosing volume of 5mL/kg in order to characterize the
antihyperglycemic effects of the fractions [25]. After another
one hour, venous blood samples were obtained from the tail,
and the plasma glucose concentrations were determined by
a commercially available kit (Reanal, Budapest, Hungary)
based on the glucose oxidase-peroxidasemethod [29]. Imme-
diately after blood sampling, rats were anesthetized in 4%
isoflurane and additional blood samples were collected by
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cardiac puncture for determination of uric acid concentration
and total antioxidant capacity. Since inhalational anesthetics
are reported to substantially elevate the blood glucose level,
separate blood samplings were needed for determination of
all the planned parameters [30]. Serum samples were pre-
pared by centrifugation and stored at –70∘Cuntil the analyses.
All determinations by colorimetric uric acid (BioAassay Sys-
tems, Hayward, CA, USA) and antioxidant (Sigma-Aldrich,
Budapest, Hungary) assay kits were performed in duplicates
according to themanufacturers’ suggestions. Separate groups
orally treated with glibenclamide and trolox (10mg/kg for
both) were included as reference for the antihyperglycemic
and antioxidant assays, respectively.
3. Results and Discussion
3.1. Chemical Composition of the Fractions Obtained. The
fractions, obtained by solvent-solvent extraction and a rough
chromatographic separation of the organic phase on silica,
represented fundamentally different chemical compositions
(Figure 1). As expected, highly water soluble, hydrophilic
compounds (including iminosugars of the plant, see below)
remained in the water phase (Figure 1(b)), while most of
the still polar chlorogenic acid (1) could already be detected
in the organic phase (Figure 1(c)) along with vast major-
ity of the supposedly “drug-like” secondary metabolites of
mulberry leaves. These would be the compounds with the
highest probability for therapeutic value; mainly the too low
log 𝑃 value typically results in poor penetration through
membranes (iminosugars, a constituent group of possible
exception to this, are discussed below). As seen from the
DAD fingerprints, FR1 (Figure 1(d)) and FR2 (Figure 1(e))
mostly contained compounds with lower wavelengths of UV
absorbance maxima probably including several terpenoids
and/or phenylpropanes [19]. The dominant peak of FR2
was detected and quantified as loliolide (4) (0.33%), a
monoterpene lactone we have recently reported fromM. alba
leaves [19]. Of all fractions, FR3 (Figure 1(f)) contained the
smallest amount of UV absorbing material; its main con-
stituents remained unidentified. Based on its UV spectrum
and retention time, chief constituent of FR4 (Figure 1(g)) is
suggested to be a flavone aglycone (3.42–3.50%, expressed in
equivalents of isoquercitrin (3) or rutin (2)), while 3 (2.42%)
was also present in this fraction. FR5 (Figure 1(h)) contained
the majority of 3 (9.79%) along with a smaller amount
of 2 (3.77%), while the previously mentioned unidentified
flavonoid could still be detected. FR6 (Figure 1(i)), the most
polar fraction obtained from the column chromatography,
contained 1 (8.99%), 2 (10.41%), and 3 (5.64%) as major UV
active constituents.
Both the extract and the fractions contained very small
amounts of iminosugars. By means of MS/MS, 1-DN con-
tents were found as low as 0.2694‰(EX), 0.3007‰ (FR-W),
0.0742‰ (FR-B), ∼0.016‰ (FR4; around detection limit),
0.0558‰ (FR5), and 0.2770‰(FR6). On the other hand,
slope of the calibration lines of GAL-DN and fagomine is
around 13 and 6 times higher, respectively, as compared to
that of 1-DN, based on a recent publication using the same
MRM transitions with ESI-MS/MS [24]. This allowed only
a rough estimation on the quantity of these compounds by
using our calibration obtained for 1-DN. Amounts of GAL-
DN were about 0.02‰ (EX), 0.03‰ (FR-W), 0.003‰ (FR-
B) and 0.009‰(FR6), and trace amounts of this com-
pound were detected in FR4 and FR5. Fagomine contents
could be estimated as around 0.03‰ (EX), 0.04‰ (FR-W),
0.01‰ (FR-B), 0.01‰ (FR5) and 0.03‰ (FR6), with a trace
amount of this compound also present in FR4. Structures of
the compounds identified from the fractions are shown in
Figure 2.
3.2. Inhibition of Xanthin Oxidase In Vitro. All fractions were
tested at the final concentration of 5𝜇g/mL. The enzyme
activity determined in the solvent-treated condition was
considered 100% and all other conditions were compared
to that control. None of the prepared fractions exerted any
substantial action on the enzyme xanthine oxidase, while, as
expected, the reference compound allopurinol resulted in a
nearly complete (>90%) inhibition of the enzyme activity at
5 𝜇g/mL, and its IC
50
value was determined as 1.03 𝜇g/mL.
Based on these results, XO inhibition does not seem to be an
important mechanism for neither the antihyperuricemic nor
the antioxidant activity of mulberry preparations.
3.3. In Vitro Antioxidant Properties. Two different bioassays
were utilized to investigate the in vitro antioxidant properties
of the fractions: DPPH assay and lipid peroxidation (LOX)
assay. Even though the results obtained by these twomethods
are frequently parallel, certain agents can exhibit substantial
differences in these assays [31]. Generally, a compound
effective in the DPPH assay can be considered as a free
radical scavenger functioning in an organic solvent against
a chemically pure molecule (i.e., the DPPH radical). LOX
assay, on the other hand, is performed in a more complex ex
vivo biological system containing lipidswith unsaturated fatty
acids; a substance active in this assay may protect these lipids
from the spontaneous oxidation in aqueous conditions.
DPPH assay was performed with the concentration range
of 0.001–0.15mg/mL to characterize the free radical scav-
enging capacity of the prepared fractions. Fractions FR1
and FR2 exhibited no substantial activities in the utilized
concentrations. Fractions FR3 and FR4 were moderately
active, while FR5 and FR-W showed the highest potencies.
FR6, containing significant amounts of phenolic compounds
(compounds 1–3), was equipotent with the reference agent
trolox. In agreement with these, lipid peroxidation assay
showed that the antioxidant capacities of fractions FR3 and
FR6 were close to that of trolox, while FR5 and FR-W were
slightly less active. Fractions FR2 andFR4 exhibitedmoderate
activities, and, similarly to the case of the DPPH assay, FR1
was inactive. Results of both assays are summarized inTable 1.
3.4. Effect on the In Vitro Glucose Consumption of Adipocytes.
Although some minor changes could be observed in this
bioassay, no statistically significant activities were found.
This was somewhat surprising, since a lipophilic fraction,
obtained by a simple solvent-solvent distribution from the
hot water extract of the same plant collection, was previously
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Figure 1: HPLC-DAD fingerprints of the samples and the correspondingmaximum absorbance chromatograms from 𝜆 = 200 to 450 nm. (a)
Crude extract (EX), (b) FR-W, (c) FR-B, and (d)–(i) FR1-FR6, respectively.Marked peaks represent chlorogenic acid (1), rutin (2), isoquercitrin
(3), loliolide (4), and an unidentified flavone derivative (f).
found to exert strong effect in this test [19]. The most likely
explanation is the low relative amount of the constituents
responsible for this effect, based on which we can also
conclude that increasing the glucose consumption of adipose
tissue has little importance in the complex anti-diabetic
activity of less processed phytotherapeutics originated from
mulberry leaves.
3.5. Determination of the Antihyperuricemic Effects of the
Fractions In Vivo. The serum uric acid concentration in rats
is considerably low because it is metabolized into allantoin
by the enzyme uricase. Therefore, uric acid accumulation
was induced by a single administration of K-oxonate for
the in vivo investigation of the antihyperuricemic properties
of the fractions. Results are shown in Figure 3. Allopurinol
(50mg/kg intraperitoneally), used as positive control, sub-
stantially and significantly decreased the accumulation of
uric acid. The lowest dose (30mg/kg) of FR1, the highest
dose (120mg/kg) of FR2, and 60mg/kg of FR5 exerted
antihyperuricemic actions comparable to that of allopurinol.
Unexpectedly, treatment with FR-W (60 and 120mg/kg)
resulted in an elevation of serum uric acid levels. No clear
dose-response relationships were detected for some of the
fractions.
The renal excretion of uric acid is a complex and species-
dependent procedure involving its glomerular filtration,
tubular secretion, and tubular reabsorption. Since these
processes can independently be modulated with exogenous


























































1 2: R = 𝛼-L-rhamnopyranosyloxy
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4
Figure 2: Chemical structures of the compounds identified in the fractions: chlorogenic acid (1), rutin (2), isoquercitrin (3), loliolide (4),



































































































































































































Figure 3: In vivo antihyperuricemic activity of the fractions obtained. Hyperuricemia was induced by a single administration of K-oxonate,
50mg/kg of allopurinol was used as positive control, and samples were tested at 30, 60, and 120mg/kg. ∗ and ∗∗: 𝑃 < 0.05 and 0.01,
respectively, as compared to the negative control by means of one-way ANOVA followed by Dunnett’s multiple comparison test; 𝑛 = 8.
substances, the overall action of a drug is frequently biphasic.
Aspirin at dosages of >3 g/day promotes uricosuria by inhibi-
tion of the reabsorption while lower dosages (1-2 g/day) may
cause uric acid retention, presumably by interfering with the
tubular secretion [32]. This, together with the chemical com-
plexity of the fractions, could provide a simple explanation for
the unclear dose-response relationships observed in certain
cases; several interactions between various constituents of the
fractions might take place, in which the active components
would influence these renal functions differently.
3.6. Determination of the Serum Antioxidant Capacity. The
antioxidant capacities of the serum samples of the treated
animals were determined by means of a photometric assay in
which 2,2󸀠-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)
(ABTS) is converted into a chromogen radical cation
(ABTS∙+). The generation of radical cation is suppressed by
antioxidants and can be detected as a decrease of color inten-
sity; results of this assay are shown in Figure 4. Treatment
with trolox (10mg/kg) resulted in a substantial increase in
the antioxidant capacity (expressed as trolox equivalents) but
most of the tested fractions failed to induce significant change
in this serum parameter. The higher doses of FR6 (60 and
120mg/kg) exhibited similar antioxidant effects to that of
trolox, which effect can most likely be attributed to the high
chlorogenic acid (1), rutin (2), and isoquercitrin (3) content of
this fraction. On the other hand, 30mg/kg of FR3 decreased
the oxidative status of the serum, indicating a prooxidant
potential for certain constituents.





























































































































































































Figure 4: Effects on the serum antioxidant capacity in vivo. ∗𝑃 < 0.05 as compared to the negative control by one-way ANOVA followed by







































































































































































































Figure 5: Effects on the postprandial hyperglycemia of normal rats after starch loading.∗ and∗∗:𝑃 < 0.05 and 0.01, respectively, as compared
to the negative control by one-way ANOVA followed by Dunnett’s multiple comparison test; 𝑛 = 8. The fasting blood glucose level was
determined in preliminary experiments, and its dataset was not included in the statistical evaluation.
3.7. Determination of the Postprandial Plasma Glucose Levels.
Treatment with the positive control glibenclamide (10mg/kg)
resulted in a substantial and significant decrease of the
postprandial plasma glucose levels obtained in the starch load
model. FR1 was inactive up to 120mg/kg, while FR3 exhibited
antihyperglycemic action at all applied doses. Fractions FR2,
FR-W, and FR5 were effective at 120, 60, and 120mg/kg,
respectively. Fractions FR4 and FR6 exhibited some anti-
hyperglycemic properties but no clear dose-response rela-
tionships were observed; results are shown in Figure 5. It
is worthy to note, however, that the present in vivo model
investigated the effect of a single-dose administration on
the postprandial hyperglycemia of normal rats after starch
loading; therefore, these results can hardly be compared with
those we obtained previously for a longer treatment in type 2
diabetic rats with ad libitum access to standard food [16].
4. Conclusions
The investigated extract ofM. alba showedmultiple beneficial
bioactivities in view of both targeted chronic metabolic
diseases. It can also be concluded, based on the different
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Table 1: In vitro antioxidant activities as calculated from the DPPH
assay and from the inhibition of the spontaneous lipid peroxidation.
Sample DPPH Lipid peroxidation









Trolox: positive control in both cases.
aExhibited no substantial activity in the applied concentration range.
effects exerted by the fractions, that separate compound
groups are responsible for the individual actions, which have
a significant potential for a positive combined effect.
FR1, FR2, and FR5 are of interest in view of the anti-
hyperuricemic activity as potential uricosuric agents. FR2–6
were all found valuable for their antihyperglycemic activities,
but FR3 was the strongest exerting significant effects at all
administered doses. Somewhat unsurprisingly, FR6, contain-
ing most of the phenolic constituents, was found to be the
strongest antioxidant both in vitro and in vivo, which makes
this fraction particularly useful against the high oxidative
stress present in both diabetes and chronic hyperuricemia.
Furthermore, considering our original objectives, frac-
tions of relatively low value could also be revealed. Although
the water phase of the first solvent-solvent extraction (FR-
W) could effectively scavenge DPPH radicals in vitro and
showed at least a weak antihyperglycemic activity in vivo
(possibly due to the low iminosugar content of our sample),
this fraction was also found to significantly increase the
plasma uric acid levels; hence, it is potentially unwanted in
a well-designed mulberry preparation. FR1, the less polar
fraction that was eluted with dichloromethane from the silica
column, was found inactive in most bioactivity tests except
for its non-dose-dependent antihyperuricemic activity at 30
mg/kg in vivo. This might be of interest for further research,
but, due to the nearly 20% amount of this fraction by weight
in the dry butanolic phase, removing this polarity range of
constituents could as well be considered for increasing the
overall therapeutic benefits of a phytotherapeutic product.
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